Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enzychem Lifesciences Selected to Collaborate with NIAID CCRP on the CERF Program","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Enzychem Lifesciences Corporation"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size
            filter Upfront Payment

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Companies

              Enzychem Lifesciences Corporation

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Enzychem Lifesciences Selected to Collaborate with NIAID CCRP on the CERF Program

              Details:

              Enzychem's lead compound, EC-18, is an immunomodulator that rapidly resolves inflammation and restores immune homeostasis by accelerating the intracellular trafficking of pattern recognition receptor-bound pathogenic invaders or endogenous danger signals.

              Lead Product(s): EC-18

              Therapeutic Area: Pharmacology/Toxicology Product Name: EC-18

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: National Institutes of Health

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 20, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY